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Abstract: Breast cancer is the most common malignancy among women worldwide, and the main 
cause of death in patients with breast cancer is metastasis. Metastasis to the central nervous system 
occurs in 10% to 16% of patients with metastatic breast cancer, and this rate has increased because 
of recent advancements in systemic chemotherapy. Because of the various treatments available for 
brain metastasis, accurate diagnosis and evaluation for treatment are important. Magnetic resonance 
imaging (MRI) is one of the most reliable preoperative examinations not only for diagnosis of 
metastatic brain tumors but also for estimation of the molecular characteristics of the tumor based on 
radiographic information such as the number of lesions, solid or ring enhancement, and cyst formation. 
Surgical resection continues to play an important role in patients with a limited number of brain 
metastases and a relatively good performance status. A single brain metastasis is a good indication for 
surgical treatment followed by radiation therapy to obtain longer survival. Surgical removal is also 
considered for two or more lesions if neurological symptoms are caused by brain lesions of >3 cm  
with a mass effect or associated hydrocephalus. Although maximal safe resection with minimal morbidity 
is ideal in the surgical treatment of brain tumors, supramarginal resection can be achieved in select cases. 
With respect to the resection technique, en bloc resection is generally recommended to avoid leptomeningeal 
dissemination induced by piecemeal resection. An operating microscope, neuronavigation, and intraoperative 
neurophysiological monitoring are essential in modern neurosurgical procedures, including tumor resection. 
More recently, supporting surgical instruments have been introduced. The use of endoscopic surgery has 
dramatically increased, especially for intraventricular lesions and in transsphenoidal surgery. An exoscope 
helps neurosurgeons to comfortably operate regardless of patient positioning or anatomy. A tubular retractor 
can prevent damage to the surrounding brain tissue during surgery and is a useful instrument in combination 
with both an endoscope and exoscope. Additionally, 5-aminolevulinic acid (5-ALA) is a promising reagent for 
photodynamic detection of residual tumor tissue. In the near future, novel treatment options such as high-
intensity focused ultrasound (HIFU), laser interstitial thermal therapy (LITT), oncolytic virus therapy, and 
gene therapy will be introduced.
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Introduction
Breast cancer is the most common malignancy among 
women worldwide, and a recent database review showed 
that 20% to 30% of patients with breast cancer develop 
metastasis as the main cause of death (1,2). Approximately 
10% to 16% of patients with metastatic breast cancer 
develop brain metastases (3,4), and this rate is increasing as 
more people are living longer with a primary diagnosis (5). 
Most patients with brain metastasis have shorter survival 
because of progressive systemic disease or uncontrolled 
neurological disease. The median survival of patients with 
breast cancer after relapse in the central nervous system 
ranges from 5 to 14 months (6). Recent advancements in 
adjuvant treatments such as anti-human epidermal growth 
factor receptor-2 (anti-HER-2) monoclonal antibody 
have made extracranial lesions more controllable, thus 
increasing the likelihood that brain metastasis is the 
first site of recurrence and that appropriate treatment 
of brain metastasis will lead to longer survival (7). The 
treatment of brain metastasis includes corticosteroids, 
surgery, radiosurgery or radiotherapy, chemotherapy, and 
immunotherapy. Surgical treatment of brain metastasis 
has been significantly developed with advancements in 
supporting neurosurgical tools and technologies. The 
purpose of this review is to discuss the characteristics and 
surgical treatment of metastatic brain tumors from breast 
cancer.
Characteristics of metastatic brain tumors of 
breast cancer
Imaging modalities are necessary to detect and differentiate 
cerebral neoplasms from other nonmalignant tumors. 
Intracranial metastases typically show enhancement with 
contrast reagent because of destruction of the blood-brain 
barrier. Metastases generally occur as cortical or subcortical 
lesions because of hematogenous spread and often start as 
smaller and solidly enhancing lesions that become ring-
enhancing lesions secondary to necrosis (8). Many common 
malignancies, including breast, colon, renal cell, and thyroid 
cancers, often develop a single brain metastasis, whereas 
lung cancer and melanoma are more likely to develop 
multiple brain tumors (9). Nodular solid enhancement can 
be found in a variety of pathologies, including metastatic 
disease, lymphoma, sarcoids, vasculitides such as Behçet’s 
disease, demyelinating disorders, and bacterial or fungal 
infections (10). In contrast, the most common etiology of 
ring-enhanced lesions is high-grade glioma (40%), followed 
by metastases (30%), abscesses (8%), and demyelinating 
disease (6%) (11). Standard magnetic resonance imaging 
(MRI) sequences such as T2-weighted imaging, diffusion-
weighted imaging, and contrast-enhanced T1-weighted 
imaging can distinguish between metastases and other 
clinical conditions, although differentiating a single 
metastasis from a glioblastoma remains a top diagnostic 
challenge. Pope (10) reviewed the neuroimaging features of 
metastatic brain tumors and found that magnetic resonance 
spectroscopies and relative cerebral blood volumes seem to 
help differentiate metastases from glioblastomas.
MRI is one of the most reliable modalities with which 
to evaluate metastatic brain tumors, although very few 
studies in the literature have reported the relationships 
between MRI features and the histology of tumors. Yeh 
et al. (12) retrospectively analyzed the MRI features of 
brain metastasis from different subtypes of recurrent breast 
cancer for subclassification. In that study, the patients were 
categorized as having luminal type, HER-2-enriched type, 
or triple-negative breast cancers, and all MRI examinations 
were performed on a 1.5-Tesla MRI scanner. Both the 
patients with luminal type cancers and those with HER-2 
enriched type cancers showed solid tumors with or without 
perifocal edema, whereas most patients with triple-negative 
breast cancers showed distinct features of cystic and 
necrotic lesions. Brain metastatic lesions frequently show 
characteristics different from those of the primary tumor 
histologically and genetically (13-15), indicating that MRI is 
a desirable modality with which to explore the tumor nature 
of brain metastasis (12).
Tumor invasion into surrounding central nervous system 
tissues should be considered when resecting brain tumors. 
Glioblastoma, one of the primary central nervous system 
tumors, is difficult to totally remove surgically because 
tumor cells can infiltrate the surrounding tissue far beyond 
the tumor core (16). In contrast, metastatic brain tumors 
are less invasive. Baumert et al. (17) histologically evaluated 
the invasiveness of metastatic brain tumors and found that 
breast cancer infiltrated the surrounding tissue up to 1 mm 
from the tumor core. Therefore, gross total removal of 
breast cancers can be achieved by resecting the tumor with 
an additional margin from the tumor border.
Indications for surgical treatment
Surgical resection continues to play an important role in 
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patients with a limited number of brain metastases and a 
relatively good performance status. In the early 1990s, three 
randomized trials on single brain metastasis were conducted 
to evaluate the efficacy of surgical resection followed by 
whole-brain radiation therapy compared with whole-brain 
radiation therapy alone, and the data indicated that surgical 
resection significantly prolonged overall survival in patients 
without active systemic disease and with a higher Karnofsky 
performance status (18-20). According to the JCOG0504 
trial, surgical resection followed by salvage stereotactic 
radiosurgery (SRS) has been established as a standard 
therapy for patients with fewer brain metastases (21). SRS 
is also the effective alternative to surgical treatment for 
a single metastasis (22,23), but the higher doses of SRS 
increase the risk of the late effect of radiation necrosis (24). 
In addition, brain edema caused by metastatic brain tumors 
resolves significantly faster after surgical resection than 
after SRS (25). Moreover, in patients with neurological 
symptoms caused by brain lesions of >3 cm with a mass 
effect or associated hydrocephalus, surgical resection can 
immediately alleviate these symptoms (26). Instead, surgical 
resection followed by SRS can be considered as standard 
treatment in patients with a few (three or fewer) brain 
metastases, mainly with lesions of >3 cm in diameter (26).
The Congress of Neurological Surgeons published 
guidelines for the surgical treatment of metastatic brain 
tumors (23,27). In these guidelines, the indication for 
surgical resection of metastatic brain tumors is considered 
separately according to whether the patient has a single 
tumor or multiple tumors. Surgery followed by whole-
brain radiation therapy is recommended as the first-line 
treatment in patients with a single brain metastasis with 
a favorable performance status and limited extracranial 
disease. In patients with multiple brain metastases, however, 
tumor resection is recommended only in patients with 
symptomatic lesions with a mass effect or hydrocephalus. 
The Japan Society for Neuro-Oncology also recently 
disclosed clinical guidelines for metastatic brain tumors (28). 
For a single brain lesion, surgical treatment is considered 
equivalent to radiation therapy. Tumor removal is also 
recommended in patients with two to four brain metastases 
if they have a higher Karnofsky performance status and 
the tumor locations are resectable. For patients with five 
or more brain lesions, the indication for surgical resection 
is limited to those in whom surgery is expected to provide 
functional and survival benefits. These guidelines are 
expected to change with the emergence of new treatment 
modalities in the near future.
Surgical strategy for metastatic brain tumors
Complete removal of metastatic brain tumors, termed gross 
total resection (GTR), is the ideal goal in surgical treatment. 
According to the latest guidelines published by the 
Congress of Neurological Surgeons, GTR is recommended 
over subtotal resection to improve overall survival and 
prolong the time to recurrence (23). However, recurrence 
affects about 20% of patients even after treatment with 
GTR followed by SRS (29). In contrast to diffusely invading 
tumors such as gliomas, metastatic brain tumors are 
more often well demarcated masses surrounded by gliotic 
tissue (26). Several reports have shown that supramarginal 
resection achieved by additional 5-mm surrounding tissue 
resection from the tumor edge improved the local control 
rate compared with conventional GTR (30-32). Even for 
brain metastasis in eloquent areas, supramarginal resection 
can be achieved with awake surgery in many cases (33). 
However, supramarginal resection cannot prevent 
temporary deficits such as supplementary motor area 
syndrome even with intraoperative neurophysiological 
monitoring or awake surgery (34). Therefore, deliberative 
planning for maximal safe resection with minimal tissue 
trauma is ideal for both surgeons and patients.
Tumor resection is usually performed either in a 
piecemeal fashion or en bloc fashion. Piecemeal resection 
involves debulking the mass and subsequently removing 
the capsule, which is traditionally performed. Although 
this technique can achieve GTR, it is associated with a risk 
of local recurrence and dissemination. Suki et al. (35,36) 
evaluated the rate of leptomeningeal disease after resection 
of supra- and infratentorial metastasis and found that only 
5.7% of patients who had undergone en bloc resection 
developed leptomeningeal disease compared with 13.9% 
of patients who had undergone piecemeal resection. In en 
bloc resection, the tumor is safely dissected along the brain-
tumor interface, avoiding exposure of the tumor itself to the 
surrounding tissue (37). However, this recurrence-lowering 
effect of en bloc resection is diminished in the surgical 
treatment of tumors larger than 9.71 cm3 (38). Additionally, 
piecemeal resection is inevitable in certain situations, such 
as tumors that are adherent to or infiltrating eloquent 
areas (39). Based on these reports, en bloc tumor resection is 
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basically recommended to decrease leptomeningeal disease 
when resecting a single brain metastasis (23).
Resection of cystic tumors
Cystic brain metastasis of breast cancer is associated with 
a poor prognosis (40). In the surgical treatment of cystic 
tumors, entire removal of the cyst wall is necessary to 
achieve GTR because of the higher risk of leptomeningeal 
dissemination (41). Cyst puncture is sometimes performed 
to decompress the tumor during surgery, but the boundary 
between the tumor and the surrounding brain tissue 
becomes indistinct by cyst shrinkage. Tomita et al. (42) 
introduced a technique for visualization of the inner cyst 
wall by injection of pyoktanin blue solution diluted in 
0.3% saline. Although tumor dissemination is a potential 
concern when performing cyst puncture, solidification 
with fibrin glue might prevent dissemination and enable 
easier dissection of the tumor from the surrounding brain 
tissue (43).
Supporting devices for safe GTR
Microscopic surgery
Operative equipment with which to clearly observe the 
surgical field is essential in modern neurosurgery. An 
operating microscope provides detailed views of the 
neurovascular microstructures, and such microscopes have 
been routinely adopted worldwide for almost all cranial 
and spinal surgeries (44-46). Moreover, the microscope can 
be linked to other image-guiding instruments. Fluorescein 
or indocyanine green with the dedicated microscope filter 
can help to increase the extent of resection in patients with 
cerebral metastasis (47,48).
Neuronavigation
The use of an intraoperative frameless stereotactic 
navigation device, so-called “neuronavigation”, has been 
developed as an essential tool for complicated interventions 
including the surgical treatment of malignant tumors 
during the past few decades (49,50). A neuronavigation 
system allows the surgeon to relate the physical location 
of a tumor with the preoperative images such as computed 
tomography, MRI, positron emission tomography, and 
functional MRI (51). This enables an understanding of the 
surgical target and surrounding brain tissue anatomy and 
identification of the resection site (Figure 1A,B,C). There 
are two types of neuronavigation: optical neuronavigation 
and electromagnetic neuronavigation. The optical system 
allows the use of a variety of metal tools during surgery. 
However, the advantage of electromagnetic neuronavigation 
is elimination of the optical line-of-sight problem (52-54). 
The usefulness of electromagnetic neuronavigation is 
especially evident during endoscopic surgery for sellar 
lesions and ventricular lesions (55-57). The accuracy is high 
and comparable for both types of neuronavigation (58). 
One limitation of using a navigation system is that brain 
shift reduces the accuracy of surgical guidance. Brain shift 
is caused by cerebrospinal fluid leakage after cutting the 
dura mater, gravity, and the shift of surrounding brain 
tissue back to the resection cavity (59-61). Gerard et al. (51) 
reviewed 26 studies focusing on brain shift in neurosurgical 
intervention. No universal measurement technique was 
available to detect brain shift; thus, the degree of maximal 
brain shift widely ranged from 2.3 to 30.9 mm. In their 
review, Gerard et al. (51) concluded that one of the 
causes of brain shift is localization error of the pointer 
or measuring tool. Registration error immediately after 
patient-to-image registration reportedly ranges from 1 to 
6 mm (62). Several techniques to minimize the influence of 
brain shift have been reported. Intraoperative MRI, which 
provides real-time feedback on the extent of resection and 
residual neoplasm, can overcome the brain shift problem 
by updating the source images used for neuronavigation 
(63,64). Additionally, the navigation-guided fence post 
procedure before cutting of the dura mater is a useful 
and safe technique to avoid brain shift during tumor 
resection (65). Several recent reports have indicated that 
intraoperative ultrasound combined with neuronavigation 
can improve the accuracy of neuronavigation during the 
surgery (66,67).
Neurophysiological monitoring
The use of intraoperative neurophysiological monitoring is 
essential to predict and prevent postoperative neurological 
deficits. Effective intraoperative mapping and monitoring 
techniques have developed in the context of glioma surgery 
(68-71). The purpose of intraoperative monitoring is to 
reliably identify cortical areas and subcortical pathways 
including motor, sensory, language, and cognitive functions 
(72,73), which leads to safe maximal resection of the 
tumor. A prospective controlled study showed that the use 
of intraoperative monitoring could achieve an equivalent 
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extent of resection in both eloquent and non-eloquent 
areas (74). Zhang et al. (71) retrospectively evaluated the 
long-term functional and survival outcomes of patients 
with glioma after tumor resection with intraoperative 
neurophysiologic monitoring and reported that localization 
of gliomas in eloquent areas should no longer be viewed 
as a poor prognostic factor. Intraoperative monitoring of 
the motor systems was recently reported to help reduce 
surgery-related motor deficits also for surgical resection of 
metastatic brain tumor (75-77). For metastatic brain tumors, 
supramarginal resection including additional removal of the 
adjacent brain tissue is desired to prevent local recurrence 
(30,32). Therefore, intraoperative neurophysiological 
monitoring provides important functional information 
during resection of tumors, especially when the extent of 
resection reaches an eloquent area (77).
Leading-edge surgical instruments and 
techniques
Endoscope and exoscope
During the past two decades,  endoscopic surgery 
has dramatically increased, especially in surgery for 
intraventricular lesions and in transsphenoidal surgery. 
Additionally, the visualization of deep structures is often 
better with an angled endoscope than a microscope (78). An 
endoscope has several characteristics that complement those 
of a microscope, making an endoscope a useful adjunct to 
microsurgery with a microscope (79,80). Recently, exoscope 
Figure 1 Representative case using an optical navigation system. (A) Microscopic view before skin incision, (B) intraoperative navigation 
image, and (C) intraoperative microscopic view. The microscope linked to the neuronavigation system displays the tumor boundary (arrow) 
and motor fiber (white arrowhead). A tubular retractor is used in combination (yellow arrowhead). Based on Kurozumi K. Proper use of 
optical or electromagnetic neuronavigation system in neurosurgery. Curr Pract Neurosurg 2017:83-8; with permission.
A B
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systems such as the video telescope operating monitor 
(VITOM; Karl Storz GmbH & Co., Tuttlingen, Germany) 
and ORBEYE (Sony Olympus Medical Solutions, Tokyo, 
Japan) were introduced as an alternative to a microscope 
and an endoscope. An exoscope enables surgeons to 
stand upright in a comfortable head-up position during 
surgery regardless of patient positioning or anatomy and 
provides outstanding image quality in a display (81-84). 
Moreover, development of three-dimensional technology 
in the exoscope provides a high perception of depth and 
surgical dissection techniques comparable with those of 
a microscope (85-88). Several studies have shown the 
effectiveness of an exoscope for surgical resection of 
metastatic brain tumors (89,90). In the future, all surgeries 
will be performed with a microscope, endoscope, exoscope, 
or a combination of these modalities according to the tumor 
site.
Tubular retractor
During surgical treatment of deep-seated lesions, obtaining 
a safe corridor into the tumor and visualizing the interface 
between the tumor and surrounding structures are 
important (91). Various kinds of brain retraction systems 
combined with a microscope or endoscope have been 
introduced to achieve these goals. The self-retaining 
retraction system was first introduced by Greenberg (92) 
in 1981. This system is widely used in brain surgery, 
although it is associated with a risk of brain infarction 
and brain damage due to excessive brain retraction 
pressure (93-95). Many recent reports have indicated the 
effectiveness of tubular retractors such as the ViewSite 
(Vycor Medical Inc., Boca Raton, FL, USA) (Figure 1C) 
(55,96-101). The ViewSite tubular retractor has a plastic 
body with a tapered end, which allows adjacent tissue to be 
visualized. Additionally, the ViewSite tubular retractor can 
be held with a self-retracting arm to prevent shifting of the 
operative field (101). Moreover, an endoscope and modified 
surgical instruments for endoscopic surgery can overcome 
the disadvantage of limited working space by the ViewSite 
retractor itself (55). The use of tubular retractors with 
an exoscope has recently shown promising results in the 
surgical resection of metastatic brain tumors (89,90,102).
Photodynamic detection
Increas ing  a t tent ion has  recent ly  been g iven to 
5-aminolevulinic acid (5-ALA) (103-107), a precursor 
molecule in the heme biosynthetic pathway. Previous 
studies have demonstrated that both primary and 
metastatic brain tumors preferentially take up exogenous 
5-ALA and store it as protoporphyrin IX (108,109). 
Several studies have demonstrated the usefulness of 
5-ALA for surgical resection of metastatic brain tumors, 
including breast cancer (110-113). Marbacher et al. (113) 
assessed the frequency of positive 5-ALA fluorescence in 
a cohort of patients with metastases and found that 71% 
of the metastatic brain tumors from breast cancer were 
5-ALA fluorescence-positive. Another study showed that 
the fluorescence intensity of 5-ALA was high in both 
the sentinel lymph node and primary lesion of breast 
cancer; thus, 5-ALA shows promise in the detection of 
metastatic tumors from breast cancer (114). Moreover, the 
combination of fluorescence and intraoperative monitoring 
has been shown to be effective with respect to resection 
radicality and functional preservation (115).
Future directions
High-intensity focused ultrasound (HIFU)
HIFU was recently proposed as a type of thermal therapy. 
HIFU has been successfully applied to the treatment of 
essential tremor (116). Modern HIFU treatment systems, 
called MRI-guided focused ultrasonography (MRgFUS) 
units, have evolved to include intraprocedural anatomy- 
and temperature-sensitive MRI guidance and hemispherical 
multi-element phased-array transducers, leading to 
accurate coagulation against the lesion (117). In the field 
of neurology, MRgFUS has been approved by the US 
Food and Drug Administration (FDA) for the treatment of 
essential tremor, chronic neuropathic pain, parkinsonism, 
and Parkinson’s disease. MacDonald et al. (72) reported 
the clinical application of MRgFUS in three patients with 
glioblastoma, which was the first time that an ultrasound 
beam was focused in a brain tumor through an intact skull. 
Additionally, Coluccia et al. (118) reported the effectiveness 
and safety of MRgFUS for recurrent glioblastoma. 
Regarding the application of MRgFUS to metastatic brain 
tumors, two clinical trials (NCT 00147056 and NCT 
01473485: clinicaltrials.gov) are currently ongoing to 
verify the safety and efficacy of MRgFUS against brain 
tumors, whereas the reporting of another study’s findings 
is pending (NCT01698437). Moreover, HIFU has been 
used for palliation in patients with bone metastasis and 
in the treatment of breast cancer (119). MRgFUS can 
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temporarily permeabilize the blood-brain barrier by its non-
thermal effects on the targeted tissue (120-122), leading to 
prospective treatments of brain tumors (including breast 
cancer metastasis) such as targeted agents, nanoparticles, 
and immunotherapies (123-126).
Laser interstitial thermal therapy (LITT)
LITT is another thermal therapy for intracranial lesions 
and epilepsy, and it was approved as an ablation therapy by 
the FDA in 2007 (127). The mechanism of LITT involves 
the release of thermal energy caused by light absorption and 
scatter, which raises the temperature to 50 to 100 ℃ and 
results in coagulation necrosis (128). LITT can be used to 
both achieve a pathological diagnosis and perform ablative 
therapy (129). Additionally, a major benefit of LITT is the 
shorter recovery time and hospitalization period, especially 
in asymptomatic patients. In contrast, a drawback of LITT 
is the risk of significant postablation edema, especially in 
patients with tumors of >9 cm3 (130-132). LITT is reportedly 
as effective as conventional surgical resection for recurrent 
irradiated brain metastasis (129). Clinical trials involving 
LITT showed improved survival in patients with recurrent 
metastatic brain tumors although the varied pathology of the 
metastatic lesions limited the interpretation (133). Because 
insufficient evidence is available to make a recommendation 
regarding the use of LITT at this time (134), further 
prospective studies are needed to demonstrate the utility of 
LITT.
Oncolytic virus therapy and gene therapy
Oncolytic virus therapy has been described as a prospective 
treatment option that selectively targets cancer. Various 
types of oncolytic viruses have been engineered to increase 
the effectiveness of this treatment and have been shown 
to improve the therapeutic effect in preclinical research 
(135,136). We have also evaluated combination therapy 
with genetically engineered oncolytic viruses and systemic 
treatments such as molecular targeting drugs in mouse 
glioma models (Figure 2A,B,C) (137-139). Administration 
of talimogene laherparepvec into the tumor improved the 
durable response rates in a randomized phase III clinical 
trial (140), for which the FDA approved the use of this 
oncolytic virus for patients with recurrent melanoma. 
Moreover, phase I and II trials of HF10 in patients with 
malignant tumors, including recurrent metastatic breast 
carcinoma, have been successfully conducted (141). 
Although no oncolytic viruses have been approved for the 
treatment of brain tumors, we are now starting a phase I/
II study evaluating the safety and effectiveness of Ad-SGE-
REIC in patients with recurrent malignant glioma as gene 
therapy. Several recent reports have shown the effectiveness 
of oncolytic viruses against brain metastasis in preclinical 
models (142-144). Therefore, oncolytic viruses and gene 
therapy can be a clinically applicable therapeutic platform 
to target metastatic brain tumors from breast cancer.
Conclusions
The incidence of metastatic brain tumors from breast 
cancer has increased because of recent advancement in 
systemic treatment. Neuroimaging of metastatic brain 
tumors can estimate the molecular subtypes of breast 
cancer, which predicts the aggressiveness of the tumor. 
Surgical resection continues to play an important role in 
patients with a limited number of brain metastases and a 
relatively good performance status. En bloc tumor resection 
is basically recommended to prevent leptomeningeal 
disease. We predict that recent advancements in supporting 
neurosurgical tools and technologies will greatly improve 
the local control rate of brain metastasis. Many preclinical 
reports have described thermal therapy, oncolytic viral 
therapy, and gene therapy. In the near future, novel 
treatment modalities will emerge and evolve into standard 
treatments.
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